Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 3, 2026Psychiatry and Clinical Neurosciences

Response to ‘Hypnotic discontinuation is not synonymous with successful deprescribing: A Taiwan perspective’

View Full Paper
Ask AI
Bookmark
Share

Authors

KKKazuhiro KuriharaUniversity of the RyukyusKSKo SugiuraUniversity College GhentASAkiyoshi ShimuraTokyo Medical University

Discussion

Loading...

Member takes

Implication

Commentary evaluates hypnotic discontinuation criteria in chronic sedative users, highlighting critical distinctions between drug cessation and successful deprescribing.

Key Points

  • To provide a clinical response regarding the distinction between merely discontinuing sedative-hypnotic medications and achieving true, patient-centered deprescribing success.
  • Authored as an expert academic response and clinical commentary discussing sedative-hypnotic cessation frameworks.
  • Differentiates between simple pharmacological cessation and structured, holistic deprescribing processes.
  • Stresses that clinical success requires evaluating sustained sleep quality and patient well-being rather than drug discontinuation alone.

Cite This Study

Kurihara et al. (2026) studied this question.

synapsesocial.com/papers/6a993600636c6408cfa7eb11https://doi.org/10.1111/pcn.70130
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Higher discontinuation with dual orexin receptor antagonists than with benzodiazepines: A Japanese claims cohort study2025 · 4 citations
  2. 2Benzodiazepine dependence and its treatment with low dose flumazenil2012 · 167 citations
  3. 3Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis2022 · 440 citations
  4. 4Suvorexant for Primary Insomnia: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials2015 · 77 citations
  5. 5Long-term effectiveness and safety of lemborexant in adults with insomnia disorder: results from a phase 3 randomized clinical trial2021 · 90 citations